Literature DB >> 35538178

Comparing EQ-5D-3L and EQ-5D-5L in measuring the HRQoL burden of 4 health conditions in China.

Guizhi Weng1, Yanming Hong1, Nan Luo2, Clara Mukuria3, Jie Jiang1,4, Zhihao Yang5,6, Sha Li7.   

Abstract

BACKGROUND: EQ-5D-3L has been used in the National Health Services Survey of China since 2008 to monitor population health. The five-level version of EQ-5D was developed, but there lacks evidence to support the use of five-level version of EQ-5D in China. This study was conducted to compare the measurement properties of both the EQ-5D-3L and EQ-5D-5L in quantifying health-related quality of life (HRQoL) burden for 4 different health conditions in China.
METHODS: Participants from China were recruited to complete the 3L and 5L questionnaire via Internet. Quota was set to recruit five groups of individuals, with one group of individuals without any health condition and one group of generalized anxiety disorder (GAD), HIV/AIDS, chronic Hepatitis B (CHB), or depression, respectively. The 3L and 5L were compared in terms of response distributions, percentages of reporting 'no problems', index value distributions, known-group validity and their relative efficiency.
RESULTS: In total, 500 individuals completed the online survey, including 140 healthy individuals, 122 individuals with hepatitis B, 107 with depression, 90 individuals with GAD and 101 with HIV/AIDS. 5L also had smoother and less clustered index value distributions. Healthy group showed different response distributions to the four condition groups. The percentage of reporting 'no problems' decreased significantly in the 5L in all domains (P < 0.01), especially in the pain/discomfort dimension (relative difference: 43.10%). Relative efficiency suggested that 5L had a higher absolute discriminatory power than the 3L version between healthy participant and the other 4 condition groups, especially for the HIV/AIDS group when the 3L results was not significant.
CONCLUSIONS: The 5L version may be preferable to the 3L, as it demonstrated superior performance with respect to higher sensitivity to mild health problems, better relative efficiency and responses and index value distributions.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  China; Disease burden; EQ-5D-3L; EQ-5D-5L; Health-related quality of life

Year:  2022        PMID: 35538178     DOI: 10.1007/s10198-022-01465-7

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  32 in total

1.  Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia.

Authors:  Richard Huan Xu; Dong Dong; Nan Luo; Eliza Lai-Yi Wong; Yushan Wu; Siyue Yu; Renchi Yang; Junshuai Liu; Huiqin Yuan; Shuyang Zhang
Journal:  Eur J Health Econ       Date:  2021-03-24

2.  Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing.

Authors:  Juan Zhu; Xin-Xin Yan; Cheng-Cheng Liu; Hong Wang; Le Wang; Su-Mei Cao; Xian-Zhen Liao; Yun-Feng Xi; Yong Ji; Lin Lei; Hai-Fan Xiao; Hai-Jing Guan; Wen-Qiang Wei; Min Dai; Wanqing Chen; Ju-Fang Shi
Journal:  Qual Life Res       Date:  2020-09-15       Impact factor: 4.147

3.  Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B.

Authors:  Y X Jia; F Q Cui; L Li; D L Zhang; G M Zhang; F Z Wang; X H Gong; H Zheng; Z H Wu; N Miao; X J Sun; L Zhang; J J Lv; F Yang
Journal:  Qual Life Res       Date:  2014-03-14       Impact factor: 4.147

4.  Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study.

Authors:  M F Janssen; A Simon Pickard; Dominik Golicki; Claire Gudex; Maciej Niewada; Luciana Scalone; Paul Swinburn; Jan Busschbach
Journal:  Qual Life Res       Date:  2012-11-25       Impact factor: 4.147

5.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Authors:  M Herdman; C Gudex; A Lloyd; Mf Janssen; P Kind; D Parkin; G Bonsel; X Badia
Journal:  Qual Life Res       Date:  2011-04-09       Impact factor: 4.147

6.  The development of new research methods for the valuation of EQ-5D-5L.

Authors:  Nancy J Devlin; Paul F M Krabbe
Journal:  Eur J Health Econ       Date:  2013-07

Review 7.  EQ-5D and the EuroQol Group: Past, Present and Future.

Authors:  Nancy J Devlin; Richard Brooks
Journal:  Appl Health Econ Health Policy       Date:  2017-04       Impact factor: 2.561

8.  Construct and criterion validity of the Euro Qol-5D in patients with systemic lupus erythematosus.

Authors:  Su-li Wang; Bin Wu; Li-an Zhu; Lin Leng; Richard Bucala; Liang-jing Lu
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

9.  Psychometric validation of the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) in Chinese patients with adolescent idiopathic scoliosis.

Authors:  Prudence Wing Hang Cheung; Carlos King Ho Wong; Jason Pui Yin Cheung; Dino Samartzis; Keith Dip Kei Luk; Cindy Lo Kuen Lam; Kenneth Man Chee Cheung
Journal:  Scoliosis Spinal Disord       Date:  2016-08-04

10.  Psychometric validation of the EuroQoL 5-dimension (EQ-5D) questionnaire in patients with spondyloarthritis.

Authors:  Helen Hoi Lun Tsang; Jason Pui Yin Cheung; Carlos King Ho Wong; Prudence Wing Hang Cheung; Chak Sing Lau; Ho Yin Chung
Journal:  Arthritis Res Ther       Date:  2019-01-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.